Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last CNY35.50 CNY
Change Today +0.40 / 1.14%
Volume 7.8M
002399 On Other Exchanges
Symbol
Exchange
Shenzhen
As of 3:00 AM 04/1/15 All times are local (Market data is delayed by at least 15 minutes).

shenzhen hepalink pharmace-a (002399) Snapshot

Open
CNY35.10
Previous Close
CNY35.10
Day High
CNY35.86
Day Low
CNY35.01
52 Week High
03/31/15 - CNY36.50
52 Week Low
05/19/14 - CNY18.11
Market Cap
28.4B
Average Volume 10 Days
11.8M
EPS TTM
CNY0.31
Shares Outstanding
800.2M
EX-Date
06/9/14
P/E TM
114.2x
Dividend
CNY0.30
Dividend Yield
0.85%
Current Stock Chart for SHENZHEN HEPALINK PHARMACE-A (002399)

Related News

No related news articles were found.

shenzhen hepalink pharmace-a (002399) Related Businessweek News

No Related Businessweek News Found

shenzhen hepalink pharmace-a (002399) Details

Shenzhen Hepalink Pharmaceutical Co., Ltd. researches and develops, produces, and sells heparin sodium API and heparin derivatives to pharmaceutical companies in China and internationally. It offers Heparin sodium for blood clotting. The company was founded in 1998 and is headquartered in Shenzhen, China.

Founded in 1998

shenzhen hepalink pharmace-a (002399) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

shenzhen hepalink pharmace-a (002399) Key Developments

Shenzhen Hepalink Pharmaceutical Co., Ltd. to Report Q2, 2015 Results on Oct 31, 2014

Shenzhen Hepalink Pharmaceutical Co., Ltd. announced that they will report Q2, 2015 results on Oct 31, 2014

Shenzhen Hepalink Pharmaceutical Co., Ltd., Special/Extraordinary Shareholders Meeting, Nov 19, 2014

Shenzhen Hepalink Pharmaceutical Co., Ltd., Special/Extraordinary Shareholders Meeting, Nov 19, 2014., at 14:23 China Standard Time. Agenda: To approve application for credit to a bank; and to approve nomination of Bu Haihua as director.

Shenzhen Hepalink Pharmaceutical Co., Ltd., Special/Extraordinary Shareholders Meeting, Sep 23, 2014

Shenzhen Hepalink Pharmaceutical Co., Ltd., Special/Extraordinary Shareholders Meeting, Sep 23, 2014., at 14:30 China Standard Time. Agenda: To consider investment in the employer pension plan of a wholly-owned subsidiary in the U.S; and to consider application for credit line to banks by the company and a wholly-owned subsidiary in the U.S.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
002399:CH CNY35.50 CNY +0.40

002399 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 002399.
View Industry Companies
 

Industry Analysis

002399

Industry Average

Valuation 002399 Industry Range
Price/Earnings 79.0x
Price/Sales 14.9x
Price/Book 3.6x
Price/Cash Flow 78.3x
TEV/Sales 11.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SHENZHEN HEPALINK PHARMACE-A, please visit www.hepalink.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.